Clinical Characteristics of the CML Patients and the Allelic Loss of Their Blast Cells at Blast Crisis
| Sample No. . | Age/Sex . | Phenotype . | Blast* (%) . | Additional Karyotypic Changes* . | Allelic Loss on Chromosome Arms . | FAL . |
|---|---|---|---|---|---|---|
| 1 | 48/M | Myeloid | 20 | 9p, 16p | 0.06 | |
| 2 | 69/F | Myeloid | 85 | T | 4q | 0.03 |
| 3 | 39/F | Myeloid | 50 | NA | 1p, 1q, 7p, 8p, 20p, 20q | 0.60 |
| 4 | 33/M | Myeloid | 30 | 0 | ||
| 5 | 45/M | Myeloid | 10 | T | 0 | |
| 6 | 45/M | Myeloid | 65 | +Ph† | 7p | 0.03 |
| 7 | 19/M | Myeloid | 30 | +Ph† | 0 | |
| 8 | 33/F | Myeloid | 21 | NA | 22q | 0.07 |
| 9 | 38/M | Myeloid | NA | der(3)t(3; 7)(p13;p13),der(7)t(3:7)(p23;p13) | 0 | |
| 10 | 39/F | Myeloid | 16 | 11q+,15q+,2q− | 0 | |
| 11 | 60/F | Myeloid | 90 | T | 11p | 0.05 |
| 12 | 60/M | Myeloid | 75 | 4p | 0.07 | |
| 13 | 52/M | Myeloid | 70 | −Y† | 1p, 18p | 0.10 |
| 14 | 50/M | Myeloid | 60 | 20q | 0.11 | |
| 15 | 73/M | Myeloid | 57 | T | 17p | 0.08 |
| 16 | 52/M | Myeloid | 66 | +Ph,+8 | 6q, 18p | 0.09 |
| 17 | 52/F | Myeloid | 58 | T | 1p, 5p, 19p, 20q | 0.18 |
| 18 | 61/F | Myeloid | 64 | T | 1p, 11q, 12p, 22q | 0.27 |
| 19 | 57/F | Myeloid | 72 | t(1; 21) | 17q | 0.03 |
| 20 | 50/M | Myeloid | 70 | T | 0 | |
| 21 | 53/F | Myeloid | 90 | T | 0 | |
| 22 | 62/M | Lymphoid | 40 | NA | 1p, 18q | 0.06 |
| 23 | 38/M | Lymphoid | 82 | −9,+18,−20,+der(1),+der(20) | 1q, 9p, 9q, 16p, 20q | 0.15 |
| 24 | 38/F | Lymphoid | 60 | +i[17q] | 0 | |
| 25 | 31/M | Lymphoid | 90 | T | 7p, 9p, 19p | 0.09 |
| 26 | 34/F | Lymphoid | 10 | T | 2p, 5q, 7p, 12p, 13q, 18q | 0.19 |
| 27 | 48/M | Lymphoid | 65 | T | 3p | 0.05 |
| 28 | 60/M | Lymphoid | 40 | T | 1p, 4p, 7p, 12q, 16q, 19p, 19q | 0.30 |
| 29 | 38/F | Lymphoid | 45 | T | 1p, 4p, 10q, 19p, 20q | 0.33 |
| 30 | 52/F | Lymphoid | 46 | T | 0 |
| Sample No. . | Age/Sex . | Phenotype . | Blast* (%) . | Additional Karyotypic Changes* . | Allelic Loss on Chromosome Arms . | FAL . |
|---|---|---|---|---|---|---|
| 1 | 48/M | Myeloid | 20 | 9p, 16p | 0.06 | |
| 2 | 69/F | Myeloid | 85 | T | 4q | 0.03 |
| 3 | 39/F | Myeloid | 50 | NA | 1p, 1q, 7p, 8p, 20p, 20q | 0.60 |
| 4 | 33/M | Myeloid | 30 | 0 | ||
| 5 | 45/M | Myeloid | 10 | T | 0 | |
| 6 | 45/M | Myeloid | 65 | +Ph† | 7p | 0.03 |
| 7 | 19/M | Myeloid | 30 | +Ph† | 0 | |
| 8 | 33/F | Myeloid | 21 | NA | 22q | 0.07 |
| 9 | 38/M | Myeloid | NA | der(3)t(3; 7)(p13;p13),der(7)t(3:7)(p23;p13) | 0 | |
| 10 | 39/F | Myeloid | 16 | 11q+,15q+,2q− | 0 | |
| 11 | 60/F | Myeloid | 90 | T | 11p | 0.05 |
| 12 | 60/M | Myeloid | 75 | 4p | 0.07 | |
| 13 | 52/M | Myeloid | 70 | −Y† | 1p, 18p | 0.10 |
| 14 | 50/M | Myeloid | 60 | 20q | 0.11 | |
| 15 | 73/M | Myeloid | 57 | T | 17p | 0.08 |
| 16 | 52/M | Myeloid | 66 | +Ph,+8 | 6q, 18p | 0.09 |
| 17 | 52/F | Myeloid | 58 | T | 1p, 5p, 19p, 20q | 0.18 |
| 18 | 61/F | Myeloid | 64 | T | 1p, 11q, 12p, 22q | 0.27 |
| 19 | 57/F | Myeloid | 72 | t(1; 21) | 17q | 0.03 |
| 20 | 50/M | Myeloid | 70 | T | 0 | |
| 21 | 53/F | Myeloid | 90 | T | 0 | |
| 22 | 62/M | Lymphoid | 40 | NA | 1p, 18q | 0.06 |
| 23 | 38/M | Lymphoid | 82 | −9,+18,−20,+der(1),+der(20) | 1q, 9p, 9q, 16p, 20q | 0.15 |
| 24 | 38/F | Lymphoid | 60 | +i[17q] | 0 | |
| 25 | 31/M | Lymphoid | 90 | T | 7p, 9p, 19p | 0.09 |
| 26 | 34/F | Lymphoid | 10 | T | 2p, 5q, 7p, 12p, 13q, 18q | 0.19 |
| 27 | 48/M | Lymphoid | 65 | T | 3p | 0.05 |
| 28 | 60/M | Lymphoid | 40 | T | 1p, 4p, 7p, 12q, 16q, 19p, 19q | 0.30 |
| 29 | 38/F | Lymphoid | 45 | T | 1p, 4p, 10q, 19p, 20q | 0.33 |
| 30 | 52/F | Lymphoid | 46 | T | 0 |
Four samples were from accelerated phase patients (No. 1, 5, 10, and 26). DNAs were extracted from bone marrow mononuclear cells from seven patients (No. 5 through 7, 23 through 26).
Abbreviations: M, male; F, female; NA, not available; T, patient who had only t(9; 22) at both the chronic phase and blast crisis.
Blast (%), additional karyotypic changes at blast crisis or accelerated phase. All but two individuals (samples No. 12 and 14) had Ph chromosome at diagnosis. Rearrangement of the BCR gene was detected at diagnosis in these two samples.
These changes were also observed in their chronic phase.